<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Med.</journal-id>
<journal-title>Frontiers in Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Med.</abbrev-journal-title>
<issn pub-type="epub">2296-858X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmed.2022.851935</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Medicine</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Lung Ventilation/Perfusion Scintigraphy for the Screening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Which Criteria to Use?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Le Pennec</surname> <given-names>Romain</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1070315/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Tromeur</surname> <given-names>C&#x000E9;cile</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Orione</surname> <given-names>Charles</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Robin</surname> <given-names>Philippe</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/500230/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Le Mao</surname> <given-names>Rapha&#x000EB;l</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>De Moreuil</surname> <given-names>Claire</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jevnikar</surname> <given-names>Mitja</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1630281/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Hoffman</surname> <given-names>Cl&#x000E9;ment</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Savale</surname> <given-names>Laurent</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Couturaud</surname> <given-names>Francis</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sitbon</surname> <given-names>Olivier</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Montani</surname> <given-names>David</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1077891/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Ja&#x000EF;s</surname> <given-names>Xavier</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Le Gal</surname> <given-names>Gr&#x000E9;goire</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sala&#x000FC;n</surname> <given-names>Pierre Yves</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/294217/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Humbert</surname> <given-names>Marc</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Le Roux</surname> <given-names>Pierre Yves</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/248824/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Service de m&#x000E9;decine nucl&#x000E9;aire, EA3878 (GETBO) IFR 148, CHRU de Brest, Universit&#x000E9; de Bretagne Occidentale</institution>, <addr-line>Brest</addr-line>, <country>France</country></aff>
<aff id="aff2"><sup>2</sup><institution>D&#x000E9;partement de M&#x000E9;decine Interne et Pneumologie, EA 3878 (GETBO), CHRU de Brest, Universit&#x000E9; de Bretagne Occidentale</institution>, <addr-line>Brest</addr-line>, <country>France</country></aff>
<aff id="aff3"><sup>3</sup><institution>AP-HP, Service de Pneumologie, DHU Thorax Innovation, H&#x000F4;pital Bic&#x000EA;tre, INSERM U999, LabEx LERMIT, Centre Chirurgical Marie Lannelongue, Universit&#x000E9; Paris-Sud</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff>
<aff id="aff4"><sup>4</sup><institution>Centre d&#x00027;Investigation Clinique, Centre Hospitalier R&#x000E9;gional et Universitaire de Brest</institution>, <addr-line>Brest</addr-line>, <country>France</country></aff>
<aff id="aff5"><sup>5</sup><institution>Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa</institution>, <addr-line>Ottawa, ON</addr-line>, <country>Canada</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Domenico Albano, University of Brescia, Italy</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Francesco Dondi, Universit&#x000E0; degli Studi di Brescia, Italy; David John Macfarlane, The University of Queensland, Australia</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Romain Le Pennec <email>romain.lepennec&#x00040;gmail.com</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Nuclear Medicine, a section of the journal Frontiers in Medicine</p></fn></author-notes>
<pub-date pub-type="epub">
<day>07</day>
<month>03</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>9</volume>
<elocation-id>851935</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>01</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>01</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2022 Le Pennec, Tromeur, Orione, Robin, Le Mao, De Moreuil, Jevnikar, Hoffman, Savale, Couturaud, Sitbon, Montani, Ja&#x000EF;s, Le Gal, Sala&#x000FC;n, Humbert and Le Roux.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Le Pennec, Tromeur, Orione, Robin, Le Mao, De Moreuil, Jevnikar, Hoffman, Savale, Couturaud, Sitbon, Montani, Ja&#x000EF;s, Le Gal, Sala&#x000FC;n, Humbert and Le Roux</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license></permissions>
<abstract>
<sec>
<title>Objective</title>
<p>The diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) is a major challenge as it is a curable cause of pulmonary hypertension (PH). Ventilation/Perfusion (V/Q) lung scintigraphy is the imaging modality of choice for the screening of CTEPH. However, there is no consensus on the criteria to use for interpretation. The aim of this study was to assess the accuracy of various interpretation criteria of planar V/Q scintigraphy for the screening of CTEPH in patients with PH.</p>
</sec>
<sec>
<title>Methods</title>
<p>The eligible study population consisted of consecutive patients with newly diagnosed PH in the Brest University Hospital, France. Final diagnosis (CTEPH or non-CTEPH) was established in a referential center on the management of PH, based on the ESC/ERS guidelines and a minimum follow-up of 3 years. A retrospective central review of planar V/Q scintigraphy was performed by three nuclear physicians blinded to clinical findings and to final diagnosis. The number, extent (sub-segmental or segmental) and type (matched or mismatched) of perfusion defects were reported. Sensitivity and specificity were evaluated for various criteria based on the number of mismatched perfusion defects and the number of perfusion defects (regardless of ventilation). Receiver operating characteristic (ROC) curves were generated and areas under the curve (AUC) were calculated for both.</p>
</sec>
<sec>
<title>Results</title>
<p>A total of 226 patients with newly diagnosed PH were analyzed. Fifty six (24.8%) were diagnosed with CTEPH while 170 patients (75.2%) were diagnosed with non-CTEPH. The optimal threshold was 2.5 segmental mismatched perfusion defects, providing a sensitivity of 100 % (95% CI 93.6&#x02013;100%) and a specificity of 94.7% (95%CI 90.3&#x02013;97.2%). Lower diagnostic cut-offs of mismatched perfusion defects provided similar sensitivity but lower specificity. Ninety five percent of patients with CTEPH had more than 4 segmental mismatched defects. An interpretation only based on perfusion provided similar sensitivity but a specificity of 81.8% (95%CI 75.3&#x02013;86.9%).</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Our study confirmed the high diagnostic performance of planar V/Q scintigraphy for the screening of CTEPH in patients with PH. The optimal diagnostic cut-off for interpretation was 2.5 segmental mismatched perfusion defects. An interpretation only based on perfusion defects provided similar sensitivity but lower specificity.</p>
</sec></abstract>
<kwd-group>
<kwd>chronic thromboembolic pulmonary hypertension</kwd>
<kwd>ventilation/perfusion scintigraphy</kwd>
<kwd>interpretation criteria</kwd>
<kwd>CTEPH</kwd>
<kwd>planar V/Q scintigraphy</kwd>
</kwd-group>
<counts>
<fig-count count="4"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="28"/>
<page-count count="8"/>
<word-count count="5361"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a rare complication of acute pulmonary embolism (PE) leading to severe right ventricular failure and death in the absence of treatment (<xref ref-type="bibr" rid="B1">1</xref>). CTEPH is characterized by the presence of macroscopic thromboembolic lesions in the proximal or distal pulmonary arteries and microscopic pulmonary vasculopathy, which obstruct blood flow and increases pressure in the pulmonary arteries (<xref ref-type="bibr" rid="B2">2</xref>). The incidence of CTEPH is probably underestimated because of non-specific symptoms and a high proportion of cases with no documented history of PE (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). Diagnosing CTEPH is a major diagnostic challenge. Without treatment, the estimated 5-years survival of patients with CTEPH is poor, around 30% in patients with a mean Pulmonary Artery Pressure (mPAP) &#x0003E;40 mmHg (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>). However, in contrast with other groups of PH, CTEPH is potentially curable thanks to various treatment modalities including surgery, balloon pulmonary angioplasty and medical therapy (<xref ref-type="bibr" rid="B7">7</xref>&#x02013;<xref ref-type="bibr" rid="B10">10</xref>).</p>
<p>According to the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) guidelines for the diagnosis and treatment of pulmonary hypertension, Ventilation/Perfusion (V/Q) lung scintigraphy is the imaging modality of choice to exclude CTEPH at an early stage of the algorithm for diagnosing PH (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>). Indeed, V/Q lung scintigraphy is superior to Computed Tomography Pulmonary Angiography (CTPA), especially with a higher sensitivity (<xref ref-type="bibr" rid="B12">12</xref>).</p>
<p>While V/Q imaging has a key role in the screening of CTEPH (<xref ref-type="bibr" rid="B13">13</xref>), there is no consensus on the interpretation criteria to be used. According to ESC/ERS recommendations (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>), V/Q lung scintigraphy is considered positive for CTEPH if there are mismatched perfusion defects, but with no indication about the size and number of defects. Tunariu et al. demonstrated the superiority of planar V/Q lung scintigraphy over CTPA using the PIOPED criteria for V/Q scan interpretation (<xref ref-type="bibr" rid="B12">12</xref>). In this study, a high probability scan (i.e. at least two segmental mismatched perfusion defects) was suggestive of CTEPH while results were unclear for patients with an intermediate probability scintigraphy. In a recent study, Wang et al. used a lower threshold (<xref ref-type="bibr" rid="B14">14</xref>). V/Q lung scintigraphy was interpreted as positive for CTEPH if there was at least one segmental or two sub-segmental mismatched perfusion defects, as proposed by the European Association of Nuclear Medicine (EANM) guidelines for the diagnosis of acute PE (<xref ref-type="bibr" rid="B14">14</xref>&#x02013;<xref ref-type="bibr" rid="B16">16</xref>). However, the pulmonary artery obstruction in patients with CTEPH is typically diffuse and multi-segmental and a low burden of pulmonary vascular obstruction, e.g., one segmental defect, is very unlikely to cause PH (<xref ref-type="bibr" rid="B14">14</xref>). On the other hand, given that V/Q lung scintigraphy is positioned as a screening tool in the diagnosis of CTEPH, a high sensitivity should remain the priority. Furthermore, an imaging technique using a perfusion-only scan along with a low-dose CT acquisitions (Q-LDCT), has been reported to exhibit adequate performance for CTEPH screening compared to V/Q lung scintigraphy, which may question the diagnostic value of V/Q mismatched defects as compared with perfusion defect regardless of the ventilation (<xref ref-type="bibr" rid="B17">17</xref>). So far, no study has evaluated and compared the diagnostic performances of V/Q scintigraphy according to interpretation criteria.</p>
<p>The aim of this study was to assess the accuracy of various interpretation criteria of planar V/Q lung scintigraphy for screening of CTEPH in patients with PH.</p>
</sec>
<sec sec-type="materials and methods" id="s2">
<title>Materials and Methods</title>
<sec>
<title>Population</title>
<p>The eligible study population consisted of consecutive patients with newly diagnosed PH referred to Brest University Hospital, France for initial assessment, and included in a French National PH registry (authorization number 842063). All patients provided written informed consent.</p>
<p>The diagnosis of precapillary PH was established according to the 2015 guidelines [mPAP &#x02265; 25 mmHg and pulmonary artery wedge pressure (PAWP) &#x02264; 15 mmHg measured by right heart catheterization (RHC)] (<xref ref-type="bibr" rid="B18">18</xref>). Patients were managed according to ESC/ERS guidelines for the diagnosis and treatment of CTEPH (<xref ref-type="bibr" rid="B11">11</xref>), and classified into the different groups of PH based on clinical and imaging data. All patients with a possible CTEPH after initial assessment were referred to the National reference center in Paris Kremlin-Bic&#x000EA;tre, France, for diagnostic confirmation and to assess operability. The diagnosis of CTEPH was confirmed according to ESC/ERS guidelines (<xref ref-type="bibr" rid="B11">11</xref>). All patients diagnosed with CTEPH had pre-capillary PH diagnosed with RHC and typical morphological lesions of CTEPH on high resolution CT and/or conventional pulmonary angiography. All patients were followed up for minimum 3 years with multiple check-up review and RHC to assess evolution and avoid misdiagnosis.</p>
<p>Demographic data and history of acute PE were collected from the French PH registry. Hemodynamics results from RHC at initial screening (pulmonary vascular resistances (PVR) expressed in dyn.sec.cm<sup>&#x02212;5</sup> and mPAP expressed in mmHg) were also collected in order to evaluate the correlation between the extent of perfusion defects and the alteration of hemodynamics parameters.</p>
</sec>
<sec>
<title>V/Q Scans Acquisition and Interpretation</title>
<p>Planar V/Q lung scans were performed according to the SFMN guidelines on lung scintigraphy protocols (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B19">19</xref>). Perfusion images were obtained after administration of 140 MBq of <sup>99m</sup>Tc-macroaggregated albumin. Ventilation images were acquired either after inhalation of <sup>99m</sup>Tc-Technegas or <sup>81m</sup>Kr-Krypton gas. Imaging acquisition was performed in six views (anterior, posterior, left and right lateral, left and right posterior oblique).</p>
<p>A retrospective central review of all planar V/Q lung scintigraphy was performed by three nuclear physicians with different level of expertise, blinded to clinical results and to final diagnosis. Interpretation was determined via consensus reading. For each planar V/Q lung scintigraphy, the number, extent (sub-segmental or segmental) and type (matched or mismatched with ventilation images) of perfusion defects were reported. The extent of each defect was assessed visually. A defect was defined as segmental if it involved more than 75% of a segment and sub-segmental if it involved &#x0003C;75% (<xref ref-type="bibr" rid="B20">20</xref>).</p>
</sec>
<sec>
<title>Data Analysis</title>
<p>Continuous data were expressed as mean &#x000B1; standard deviation (SD), and categorical data were expressed as frequency and percentage (%). Differences between the two groups were analyzed for significance with the unpaired Student <italic>t</italic> test for continuous variables and with the Chi2 test for categorical variables.</p>
<p>For each planar V/Q lung scintigraphy, the number of segmental perfusion defects or equivalent (2 sub-segments = 1 segment) was computed. This was performed for mismatched perfusion defects, and for perfusion defects regardless of the ventilation (i.e., mismatched or matched defects). Receiver operating characteristic (ROC) curves were generated and areas under the curve (AUC) were calculated. For determination of the optimal diagnostic cut-off for interpretation, the main criterion was to select a high sensitivity cutoff, as V/Q lung scintigraphy is positioned as a screening tool in the diagnostic algorithm for CTEPH. Then, if various thresholds provided similar sensitivity, the threshold with the highest specificity was chosen. Correlation between the extent of perfusion defects and PAPm/PVR alteration was analyzed using Pearson correlation test.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec>
<title>Population</title>
<p>A total of 288 patients referred to the Brest University Hospital were enrolled in the French National PH registry between January 2004 and January 2019. Among those 288 patients, 62 were excluded from the present study for the following reasons: 5 patients had a well-established diagnosis of a PH attributable to left heart disease with a post-capillary PH on RHC; 19 had V/Q SPECT imaging; three had a perfusion-only scan; images were not available in 28 patients; and seven patients died before undergoing assessment.</p>
<p>A total of 226 patients with newly diagnosed PH, who underwent V/Q planar scintigraphy for the screening of CTEPH, were therefore analyzed. Out of them, 56 (25%) were diagnosed with CTEPH at the reference center in Paris. Among 170 patients (75%) diagnosed with non-CTEPH, 92 were classified in group 1 of PH classification (41%), 24 in group 2 (10%), 40 in group 3 (18%), 4 in group 5 (2%), and 10 were classified as having mixed causes PH (mix from group 1, 2 and 3) (4%). Patients&#x00027; characteristics in CTEPH and non-CTEPH groups are presented in <xref ref-type="table" rid="T1">Table 1</xref>.</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Patient baseline characteristics.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th/>
<th valign="top" align="center"><bold>CTEPH patients (<italic>N</italic> &#x0003D; 56)</bold></th>
<th valign="top" align="center"><bold>Non-CTEPH patients (<italic>N</italic> &#x0003D; 170)</bold></th>
<th valign="top" align="center"><bold><italic>p</italic>-value</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Age (years)</td>
<td valign="top" align="center">68 (SD 57&#x02013;81)</td>
<td valign="top" align="center">63 (SD 53&#x02013;78)</td>
<td valign="top" align="center"><italic>p</italic> = 0.043</td>
</tr>
<tr>
<td valign="top" align="left">No PE history (%)</td>
<td valign="top" align="center">29 (39%)</td>
<td valign="top" align="center">160 (95%)</td>
<td valign="top" align="center"><italic>p</italic> &#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">mPAP (mmHg)</td>
<td valign="top" align="center">41.6 (SD 31.4&#x02013;51.8)</td>
<td valign="top" align="center">43.2 (SD 32.4&#x02013;54.1)</td>
<td valign="top" align="center"><italic>p</italic> = 0.322</td>
</tr>
<tr>
<td valign="top" align="left">PVR (dyn.sec.cm<sup>&#x02212;5</sup>)</td>
<td valign="top" align="center">594.2 (SD 274.2&#x02013;914.2)</td>
<td valign="top" align="center">595.6 (SD 253.2&#x02013;937.9)</td>
<td valign="top" align="center"><italic>p</italic> = 0.842</td>
</tr>
<tr>
<td valign="top" align="left">Segmental mismatched perfusion defects</td>
<td valign="top" align="center">6.4 (SD 4.5&#x02013;8.2)</td>
<td valign="top" align="center">0.3 (SD &#x02212;0.95&#x02013;1.6)</td>
<td valign="top" align="center"><italic>p</italic> &#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Segmental perfusion defects</td>
<td valign="top" align="center">6.6 (SD 4.7&#x02013;8.4)</td>
<td valign="top" align="center">1.1 (SD &#x02212;0.6&#x02013;1.2)</td>
<td valign="top" align="center"><italic>p</italic> &#x0003C;0.001</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec>
<title>Patients With CTEPH Diagnosis</title>
<p>Mean age of patients was 68 years old [SD (57&#x02013;81)]. Mean time between first symptoms and diagnosis was 15 months. Among the 56 patients, 29 patients (39%) had no PE history. Planar V/Q lung scintigraphy was reported with a mean number of mismatched perfusion defects of 6.4 segments [SD (4.5&#x02013;8.2)] and a mean number of perfusion defects of 6.6 segments [SD (4.7&#x02013;8.4)]. <xref ref-type="fig" rid="F1">Figure 1</xref> illustrates a typical planar V/Q lung scintigraphy in a patient with CTEPH. Mean PAPm and PVR were 41.6 mmHg [SD (31.4&#x02013;51.8)] and 594.2 dyn.sec.cm-5 [SD (274.2&#x02013;914.2)], respectively. No correlation was found between the extent of perfusion defects and the degree of PAPm or PVR alteration: based on mismatched perfusion defects, correlation coefficients were 0.03 and 0.20 for PAPm and PVR, respectively.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>Planar V/Q scintigraphy showing multiple segmental mismatched perfusion defects in a patient with confirmed CTEPH.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-09-851935-g0001.tif"/>
</fig>
</sec>
<sec>
<title>Patients With Non-CTEPH Diagnosis</title>
<p>Mean age of patients was 63 years old [SD (53&#x02013;78)]. Mean time between first symptoms and diagnosis was 15 months. Among the 170 patients, 160 patients (95%) had no PE history. Planar V/Q lung scintigraphy was reported with a mean number of mismatched perfusion defects of 0.3 segments [SD (&#x02212;0.95-1.6)] and a mean number of total perfusion defects of 1.1 segments [SD (&#x02212;0.6&#x02013;3.2)]. Mean PAPm and PVR were 43.2 mmHg [SD (32.4&#x02013;54.1)] and 595.6 dyn.sec.cm<sup>&#x02212;5</sup> [SD (253.2&#x02013;937.9)] respectively. Among the 170 non-CTEPH patients, 103 patients had a normal planar V/Q lung scintigraphy with no perfusion defect (mismatched or matched). Planar V/Q lung scintigraphy was normal in 64/92 patients (70%) from group 1, 12/24 patients (50%) from group 2, 21/40 patients (53%) from group 3, 3/4 patients (75%) from group 5, and 3/10 patients (30%) with a mixed cause of PH. Significant differences were found between CTEPH and non-CTEPH patients for PE history (<italic>p</italic> &#x0003C; 0.0001) and age (<italic>p</italic> = 0.043). But no significant difference was found between the two groups for PAPm (<italic>p</italic> = 0.322) and RVP (<italic>p</italic> = 0.842).</p>
</sec>
<sec>
<title>Diagnostic Performance of Planar V/Q According to Various Criteria of Interpretation</title>
<p>ROC curves generated according to the number of segmental mismatched perfusion defects and segmental perfusion defects are presented in <xref ref-type="fig" rid="F2">Figure 2</xref>. <xref ref-type="fig" rid="F3">Figure 3</xref> shows the histograms of distribution of mismatched segmental perfusion defects (<xref ref-type="fig" rid="F3">Figure 3A</xref>) and segmental perfusion defects (<xref ref-type="fig" rid="F3">Figure 3B</xref>) in the CTEPH and non-CTEPH groups. Sensitivity and specificity of lung scan according to various interpretation criteria are summarized in <xref ref-type="table" rid="T2">Table 2</xref>.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p><bold>(A)</bold> Segmental mismatched perfusion defects. <bold>(B)</bold> All segmental perfusion defects (regardless of ventilation). Red points: Cut-off at 2.5 segmental; Blue points: Cut-off at 1 segmental; Black points: Cut-off at 0.5 segmental.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-09-851935-g0002.tif"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption><p><bold>(A)</bold> Histogram for V/Q scan interpreted on mismatched perfusion defects. <bold>(B)</bold> Histogram for V/Q scan interpreted on all segmental perfusion defects (regardless of ventilation). 0 = non-CTEPH patients; 1 = CTEPH patients; Red plots = positive V/Q scan; Blue plots = negative V/Q scan.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-09-851935-g0003.tif"/>
</fig>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p>Sensitivity and specificity according to criteria tested.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left" colspan="2"><bold>Criteria</bold></th>
<th valign="top" align="left"><bold>Sensitivity (%) CI 95%</bold></th>
<th valign="top" align="center"><bold>Specificity (%) CI 95%</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Mismatched perfusion defects</td>
<td valign="top" align="left">&#x02265; 2.5 segmental</td>
<td valign="top" align="center">100 (93.6&#x02013;100)</td>
<td valign="top" align="center">94.7 (90.3&#x02013; 7.2)</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">&#x02265; 1 segmental (EANM)</td>
<td valign="top" align="center">100 (93.6&#x02013;100)</td>
<td valign="top" align="center">91.8 (87.7&#x02013;95.0)</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">&#x02265; 0.5 segmental</td>
<td valign="top" align="center">100 (93.6&#x02013;100)</td>
<td valign="top" align="center">89.4 (84.9&#x02013;93.2)</td>
</tr>
<tr>
<td valign="top" align="left">Perfusion defects (regardless of ventilation)</td>
<td valign="top" align="left">&#x02265; 2.5 segmental</td>
<td valign="top" align="center">100 (93.6&#x02013;100)</td>
<td valign="top" align="center">81.8 (75.3&#x02013;86.9)</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">&#x02265; 1 segmental (EANM)</td>
<td valign="top" align="center">100 (93.6&#x02013;100)</td>
<td valign="top" align="center">66.7 (60.7&#x02013;74.7)</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">&#x02265; 0.5 segmental</td>
<td valign="top" align="center">100 (93.6&#x02013;100)</td>
<td valign="top" align="center">60.6 (53.1&#x02013;67.6)</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Based on perfusion mismatched defects, AUC was 0.98 (95%CI = 0.97&#x02013;0.99). The optimal threshold was 2.5 segmental mismatched perfusion defects, providing a sensitivity of 100 % (95%CI 93.6&#x02013;100%) and a specificity of 94.7% (95%CI 90.3&#x02013;97.2%). Lower diagnostic cut-offs provided similar sensitivity but lower specificity: 91.8% (95%CI 87.7&#x02013;95.0%) using 1 segmental mismatched defect (i.e., the EANM criteria) and 89.4% (95%CI 84.9&#x02013;93.2%) using 0.5 segmental (=1 sub-segmental) mismatched defect, respectively. Out of the 56 patients with CTEPH, 53 patients (95%) had more than 4 segmental mismatched defects.</p>
<p>Based on perfusion defects regardless of ventilation, the AUC was 0.96 (95%CI 0.93&#x02013;0.98). The optimal threshold was 2.5 segmental perfusion defects, providing a sensitivity of 100% (95%CI 93.6&#x02013;100%) and a specificity of 81.8% (95%CI 75.3&#x02013;86.9%). Lower diagnostic cut-offs provided similar sensitivity but lower specificity (See <xref ref-type="table" rid="T2">Table 2</xref>). <xref ref-type="fig" rid="F4">Figure 4</xref> illustrates a planar V/Q lung scintigraphy with multiple bilateral perfusion defects matched to the ventilation in a non-CTEPH patient.</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption><p>Planar V/Q scan showing multiple perfusion defects matched with ventilation impairments: final diagnosis was a PH classified as mix from group 1, 2 and 3 of PH classification, which was confirmed during the follow-up.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-09-851935-g0004.tif"/>
</fig>
<p>Using the optimal positivity threshold (<bold>&#x02265;</bold> 2.5 segmental mismatched perfusion defects), planar V/Q lung scintigraphy was falsely interpreted as positive for CTEPH in eight patients. Among them, four patients had a final diagnosis of PH due to advanced pulmonary disease with emphysema, chronic obstructive pulmonary disease or fibrosis with both mismatched and matched defects; one patient had pulmonary veno-occlusive disease; one patient was initially diagnosed with CTEPH but was finally classified as PH from undetermined cause during the follow up; one patient had a porto-pulmonary hypertension; and one patient had pulmonary artery abnormality anatomy from congenital cause.</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Our study confirms the high diagnostic performance of planar V/Q lung scintigraphy for screening CTEPH in patients with PH (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B14">14</xref>). The optimal diagnostic cut-off for interpretation was 2.5 segmental mismatched perfusion defects, providing a sensitivity of 100% (CI 95% 93.6&#x02013;100%) and a specificity of 94.7% (95%CI 90.3&#x02013;97.2%), respectively. Our study also demonstrates the higher diagnostic value of mismatched perfusion defects over perfusion defects (regardless of ventilation) when screening CTEPH, as an interpretation only based on perfusion defects provided similar sensitivity but a lower specificity [81.8% (95%CI 75.3&#x02013;86.9%)].</p>
<p>Diagnosing CTEPH is a major diagnostic challenge because it is the only curable form of PH (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B17">17</xref>). Given that the V/Q lung scintigraphy is used as a screening tool for a potentially surgically curable condition, the test should be as sensitive as possible, ideally close to 100%. According to current recommendations (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>), all suspected cases of CTEPH on V/Q scan are then referred to an expert center to confirm the diagnosis, which implies additional testing and travels that may be invasive and costly. Therefore, V/Q lung scintigraphy should ideally also have a high specificity in order to limit unnecessary investigations.</p>
<p>In our study, the optimal cut-off was 2.5 segmental mismatched perfusion defects, providing a sensitivity of 100% (CI 95% 93.6&#x02013;100%) and a specificity of 94.7% (95%CI 90.3&#x02013;97.2%), respectively. This cut-off is roughly similar to that of a high probability planar V/Q scintigraphy according to PIOPED criteria (i.e., two segments). In the study from Tunariu et al. (<xref ref-type="bibr" rid="B12">12</xref>), a high probability V/Q lung scintigraphy had a sensitivity of 96.2% and a specificity of 94.6%, respectively. However, results were not straightforward for patients with an intermediate probability V/Q scintigraphy. Our study clarifies this situation, with no case of CTEPH diagnosed among patients with &#x0003C;2.5 segmental perfusion mismatched defects. In a recent study, Wang et al. (<xref ref-type="bibr" rid="B14">14</xref>) used as positivity threshold 1 segmental mismatched perfusion defect or equivalent (i.e., the EANM criteria) and reported 94.2% of sensitivity and 92.8% of specificity. Using the same criteria, we found a sensitivity of 100% (95%CI 93.6&#x02013;100%) but a lower specificity of 91.8% (95%CI 87.7&#x02013;95.0%). Finally, using the modified PISAPED criteria, which were also developed for the diagnosis of acute PE, the specificity was 89.4 (84.9&#x02013;93.2) (<xref ref-type="bibr" rid="B21">21</xref>). The pulmonary artery obstruction in patients with CTEPH is typically diffuse and multi-segmental (<xref ref-type="bibr" rid="B2">2</xref>). In our study, the pulmonary vascular obstruction in patients diagnosed with CTEPH was 6.3 segmental mismatched perfusion defects on average (&#x0007E;35% of the whole lung), consistent with data from other studies (<xref ref-type="bibr" rid="B14">14</xref>). Furthermore, among patients with CTEPH, 95% had at least 4 segmental mismatched perfusion defects (&#x0007E;20% of the whole lung). Accordingly, although the V/Q lung scintigraphy is a screening tool in the management of patients with PH, not considering a single defect as a positive exam seems reasonable.</p>
<p>More recently, new imaging modalities such as CTPA, Magnetic Resonance Imaging (MRI) or perfusion scan with a Low-Dose Computed Tomography (Q-LDCT) have emerged as alternatives to lung scintigraphy to diagnose CTEPH (<xref ref-type="bibr" rid="B13">13</xref>). All these techniques rely on the analysis of lung perfusion, without information on ventilation. The need for a ventilation scan is of particular interest with the COVID-19 pandemic as the ventilation procedure increases the potential risk of contamination by the aerosol secretion and the expired air (<xref ref-type="bibr" rid="B22">22</xref>). According to our results, an interpretation only based on perfusion images demonstrated similar high sensitivity but lower specificity: 100% (95%CI 93.6&#x02013;100) and 81.8% (95%CI 75.3&#x02013;86.9%) using the same 2.5 segments cut-off. Furthermore, an interpretation based on perfusion only would have led to unnecessary refer 20 patients (12%) to the reference center. The higher specificity of mismatched perfusion defects over perfusion defects is also illustrated by the lower number of mismatched perfusion defects (0.3 segments) than of perfusion defects (1.1 segments) in the non-CTEPH group. Finally, no patient with only matched perfusion defects was diagnosed with CTEPH.</p>
<p>In this study, we only focused the analysis on planar V/Q lung scintigraphy and not on SPECT imaging. Based on an expert consensus, the recent ERS statement on CTEPH proposed to perform SPECT imaging and to provide retro-projected planar images from SPECT data. Indeed, SPECT has largely replaced planar lung scintigraphy in nuclear medicine facilities for the diagnostic of PE (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>). However, the diagnostic performance of planar images generated from V/Q SPECT is controversial (<xref ref-type="bibr" rid="B25">25</xref>) and data for V/Q SPECT in CTEPH are still sparse. Wang et al. recently reported that both techniques were highly effective for detecting or excluding CTEPH in individual patients, with no significant differences in sensitivity or specificity (<xref ref-type="bibr" rid="B14">14</xref>). Although both acute PE and CTEPH are caused by the obstruction of pulmonary arteries, their underlying pathologies differ substantially (<xref ref-type="bibr" rid="B2">2</xref>). For instance, pulmonary artery obstructions in patients with CTEPH are more diffuse and multi-segmental as demonstrated in our study with 95% of patient with CTEPH displaying more than 4 segmental mismatched perfusion defects. For the diagnosis of acute PE, SPECT has been reported to be more sensitive and to detect more perfusion defects than planar imaging. In that respect, and given that planar V/Q lung scintigraphy is already highly sensitive, the clinical relevance of using SPECT over planar scintigraphy for screening CTEPH may be questionable. The optimal diagnostic cut-off may also be higher with SPECT than with planar imaging. On the other hand, SPECT imaging may facilitate the co-registration with other imaging modality which may be of value for pre and post-operative assessment of patients with CTEPH. SPECT imaging may also better characterize micro-vascular disease by detecting peripherical perfusion amputation (<xref ref-type="bibr" rid="B13">13</xref>). Finally, it would be of interest to further assess the additional value of combining a low dose CT to SPECT imaging (SPECT/CT), which may allow to better characterize morphological abnormalities for alternative diagnosis of dyspnea and therefore increase specificity (<xref ref-type="bibr" rid="B26">26</xref>).</p>
<p>Surprisingly, no correlation was found between the extent of perfusion defects and PAPm or PVR impairment in patients with CTEPH. As reported by Azarian et al. (<xref ref-type="bibr" rid="B27">27</xref>), it could be explained by the presence of extensive microvascular disease associated with mechanical pulmonary vascular obstruction. Indeed, in our study, 3 out of the 11 patients with PVR &#x0003E; 800 dyn.sec.cm<sup>&#x02212;5</sup> showed &#x0003C;6 perfusion defects. In these patients, high PVR may be explained not only by mechanical clots but also by a suspected small-vessel disease.</p>
<p>Our study has some limitations. Firstly, the index test and the reference standard were not completely independent as the result of the V/Q scan was used to classify patients according to the different group of PH, and especially to differentiate CTEPH and non-CTEPH cause of PH. The accuracy of V/Q lung scintigraphy could therefore have been artificially increased (<xref ref-type="bibr" rid="B28">28</xref>). However, our reference standard was based on the ERS/ESC guidelines for the diagnosis and treatment of PH (<xref ref-type="bibr" rid="B11">11</xref>). All patients with possible CTEPH were addressed to the National reference center in Paris and underwent an independent extensive work-up to assess morphology of the diseased pulmonary arteries with conventional catheter pulmonary angiography or high-resolution CT. In order to avoid misdiagnosis, all patients also had a mean follow-up of 3 years. Secondly, we performed a consensus reading and did not assess interobserver reproducibility. However, principles of interpretation, based on the recognition of mismatched perfusion defects, are similar for CTEPH screening and PE diagnosis and are therefore well-known by nuclear medicine physicians.</p>
</sec>
<sec sec-type="conclusions" id="s5">
<title>Conclusion</title>
<p>In this study, we confirm the high diagnostic performance of planar V/Q lung scintigraphy for screening CTEPH in patients with PH. The optimal diagnostic cut-off for interpretation was 2.5 segmental mismatched perfusion defects, providing 100% sensitivity and 94.7% specificity, respectively. We also confirmed the need for a ventilation scan as an interpretation only based on perfusion defects provided lower specificity (81.8%) and would have led to unnecessary additional explorations in 12% of patients.</p>
</sec>
<sec sec-type="data-availability" id="s6">
<title>Data Availability Statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s7">
<title>Ethics Statement</title>
<p>Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. The patients/participants provided their written informed consent to participate in this study.</p>
</sec>
<sec id="s8">
<title>Author Contributions</title>
<p>Material preparation, data collection, and analysis were performed by RL, PL, PS, CO, and CT. The first draft of the manuscript was written by RL, PL, and CT. All authors contributed to the study conception, design, commented on previous versions of the manuscript, and read and approved the final manuscript.</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x00027;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ack><p>The authors would like to acknowledge Marie Gu&#x000E9;gan for her assistance.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Held</surname> <given-names>M</given-names></name> <name><surname>Hesse</surname> <given-names>A</given-names></name> <name><surname>Gott</surname> <given-names>F</given-names></name> <name><surname>Holl</surname> <given-names>R</given-names></name> <name><surname>Hubner</surname> <given-names>G</given-names></name> <name><surname>Kolb</surname> <given-names>P</given-names></name> <etal/></person-group>. <article-title>A symptom-related monitoring program following pulmonary embolism for the early detection of CTEPH: a prospective observational registry study</article-title>. <source>BMC Pulm Med.</source> (<year>2014</year>) <volume>14</volume>:<fpage>141</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2466-14-141</pub-id><pub-id pub-id-type="pmid">25168781</pub-id></citation></ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simonneau</surname> <given-names>G</given-names></name> <name><surname>Torbicki</surname> <given-names>A</given-names></name> <name><surname>Dorfmuller</surname> <given-names>P</given-names></name> <name><surname>Kim</surname> <given-names>N</given-names></name></person-group>. <article-title>The pathophysiology of chronic thromboembolic pulmonary hypertension</article-title>. <source>Eur Respir Rev.</source> (<year>2017</year>) <volume>26</volume>:<fpage>160112</fpage>. <pub-id pub-id-type="doi">10.1183/16000617.0112-2016</pub-id><pub-id pub-id-type="pmid">28356405</pub-id></citation></ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guerin</surname> <given-names>L</given-names></name> <name><surname>Couturaud</surname> <given-names>F</given-names></name> <name><surname>Parent</surname> <given-names>F</given-names></name> <name><surname>Revel</surname> <given-names>MP</given-names></name> <name><surname>Gillaizeau</surname> <given-names>F</given-names></name> <name><surname>Planquette</surname> <given-names>B</given-names></name> <etal/></person-group>. <article-title>Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism</article-title>. <source>Thromb Haemost.</source> (<year>2014</year>) <volume>112</volume>:<fpage>598</fpage>&#x02013;<lpage>605</lpage>. <pub-id pub-id-type="doi">10.1160/TH13-07-0538</pub-id><pub-id pub-id-type="pmid">24898545</pub-id></citation></ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonderman</surname> <given-names>D</given-names></name> <name><surname>Wilkens</surname> <given-names>H</given-names></name> <name><surname>Wakounig</surname> <given-names>S</given-names></name> <name><surname>Schafers</surname> <given-names>HJ</given-names></name> <name><surname>Jansa</surname> <given-names>P</given-names></name> <name><surname>Lindner</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>Risk factors for chronic thromboembolic pulmonary hypertension</article-title>. <source>Eur Respir J.</source> (<year>2009</year>) <volume>33</volume>:<fpage>325</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00087608</pub-id><pub-id pub-id-type="pmid">18799507</pub-id></citation></ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delcroix</surname> <given-names>M</given-names></name> <name><surname>Lang</surname> <given-names>I</given-names></name> <name><surname>Pepke-Zaba</surname> <given-names>J</given-names></name> <name><surname>Jansa</surname> <given-names>P</given-names></name> <name><surname>D&#x00027;Armini</surname> <given-names>AM</given-names></name> <name><surname>Snijder</surname> <given-names>R</given-names></name> <etal/></person-group>. <article-title>Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry</article-title>. <source>Circulation.</source> (<year>2016</year>) <volume>133</volume>:<fpage>859</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.016522</pub-id><pub-id pub-id-type="pmid">26826181</pub-id></citation></ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname> <given-names>IM</given-names></name> <name><surname>Pesavento</surname> <given-names>R</given-names></name> <name><surname>Bonderman</surname> <given-names>D</given-names></name> <name><surname>Yuan</surname> <given-names>JX</given-names></name></person-group>. <article-title>Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding</article-title>. <source>Eur Resp J.</source> (<year>2013</year>) <volume>41</volume>:<fpage>462</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00049312</pub-id><pub-id pub-id-type="pmid">22700839</pub-id></citation></ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pepke-Zaba</surname> <given-names>J</given-names></name> <name><surname>Delcroix</surname> <given-names>M</given-names></name> <name><surname>Lang</surname> <given-names>I</given-names></name> <name><surname>Mayer</surname> <given-names>E</given-names></name> <name><surname>Jansa</surname> <given-names>P</given-names></name> <name><surname>Ambroz</surname> <given-names>D</given-names></name> <etal/></person-group>. <article-title>Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry</article-title>. <source>Circulation.</source> (<year>2011</year>) <volume>124</volume>:<fpage>1973</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.015008</pub-id><pub-id pub-id-type="pmid">21969018</pub-id></citation></ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname> <given-names>D</given-names></name> <name><surname>Madani</surname> <given-names>M</given-names></name> <name><surname>Fadel</surname> <given-names>E</given-names></name> <name><surname>D&#x00027;Armini</surname> <given-names>AM</given-names></name> <name><surname>Mayer</surname> <given-names>E</given-names></name></person-group>. <article-title>Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension</article-title>. <source>Eur Respir Rev.</source> (<year>2017</year>) <volume>26</volume>:<fpage>160111</fpage>. <pub-id pub-id-type="doi">10.1183/16000617.0111-2016</pub-id><pub-id pub-id-type="pmid">28298388</pub-id></citation></ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tromeur</surname> <given-names>C</given-names></name> <name><surname>Jais</surname> <given-names>X</given-names></name> <name><surname>Mercier</surname> <given-names>O</given-names></name> <name><surname>Couturaud</surname> <given-names>F</given-names></name> <name><surname>Montani</surname> <given-names>D</given-names></name> <name><surname>Savale</surname> <given-names>L</given-names></name> <etal/></person-group>. <article-title>Factors predicting outcome after pulmonary endarterectomy</article-title>. <source>PloS one.</source> (<year>2018</year>) <volume>13</volume>:<fpage>e0198198</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0198198</pub-id><pub-id pub-id-type="pmid">29927944</pub-id></citation></ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delcroix</surname> <given-names>M</given-names></name> <name><surname>Torbicki</surname> <given-names>A</given-names></name> <name><surname>Gopalan</surname> <given-names>D</given-names></name> <name><surname>Sitbon</surname> <given-names>O</given-names></name> <name><surname>Klok</surname> <given-names>FA</given-names></name> <name><surname>Lang</surname> <given-names>I</given-names></name> <etal/></person-group>. <article-title>ERS statement on chronic thromboembolic pulmonary hypertension</article-title>. <source>Eur Respir J</source>. (<year>2021</year>) <volume>57</volume>:<fpage>2002828</fpage>. <pub-id pub-id-type="doi">10.1183/13993003.02828-2020</pub-id><pub-id pub-id-type="pmid">33334946</pub-id></citation></ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galie</surname> <given-names>N</given-names></name> <name><surname>Humbert</surname> <given-names>M</given-names></name> <name><surname>Vachiery</surname> <given-names>JL</given-names></name> <name><surname>Gibbs</surname> <given-names>S</given-names></name> <name><surname>Lang</surname> <given-names>I</given-names></name> <name><surname>Torbicki</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)</article-title>. <source>Eur Respir J.</source> (<year>2015</year>) <volume>46</volume>:<fpage>903</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1183/13993003.01032-2015</pub-id><pub-id pub-id-type="pmid">26320113</pub-id></citation></ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tunariu</surname> <given-names>N</given-names></name> <name><surname>Gibbs</surname> <given-names>SJ</given-names></name> <name><surname>Win</surname> <given-names>Z</given-names></name> <name><surname>Gin-Sing</surname> <given-names>W</given-names></name> <name><surname>Graham</surname> <given-names>A</given-names></name> <name><surname>Gishen</surname> <given-names>P</given-names></name> <etal/></person-group>. <article-title>Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension</article-title>. <source>J Nucl Med.</source> (<year>2007</year>) <volume>48</volume>:<fpage>680</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.2967/jnumed.106.039438</pub-id><pub-id pub-id-type="pmid">17475953</pub-id></citation></ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>NH</given-names></name> <name><surname>Delcroix</surname> <given-names>M</given-names></name> <name><surname>Jais</surname> <given-names>X</given-names></name> <name><surname>Madani</surname> <given-names>MM</given-names></name> <name><surname>Matsubara</surname> <given-names>H</given-names></name> <name><surname>Mayer</surname> <given-names>E</given-names></name> <etal/></person-group>. <article-title>Chronic thromboembolic pulmonary hypertension</article-title>. <source>Eur Respir J.</source> (<year>2019</year>) <volume>53</volume>:<fpage>1801915</fpage>. <pub-id pub-id-type="doi">10.1183/13993003.01915-2018</pub-id><pub-id pub-id-type="pmid">30545969</pub-id></citation></ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>L</given-names></name> <name><surname>Wang</surname> <given-names>M</given-names></name> <name><surname>Yang</surname> <given-names>T</given-names></name> <name><surname>Wu</surname> <given-names>D</given-names></name> <name><surname>Xiong</surname> <given-names>C</given-names></name> <name><surname>Fang</surname> <given-names>W</given-names></name> <etal/></person-group>. <article-title>Prospective, comparative study of ventilation-perfusion planar imaging and ventilation-perfusion SPECT for chronic thromboembolic pulmonary hypertension</article-title>. <source>J Nucl Med.</source> (<year>2020</year>) <volume>61</volume>:<fpage>1832</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.2967/jnumed.120.243188</pub-id><pub-id pub-id-type="pmid">32198309</pub-id></citation></ref>
<ref id="B15">
<label>15.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bajc</surname> <given-names>M</given-names></name> <name><surname>Schumichen</surname> <given-names>C</given-names></name> <name><surname>Gruning</surname> <given-names>T</given-names></name> <name><surname>Lindqvist</surname> <given-names>A</given-names></name> <name><surname>Le Roux</surname> <given-names>PY</given-names></name> <name><surname>Alatri</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>EANM guideline for ventilation/perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond</article-title>. <source>Eur J Nucl Med Mol imaging.</source> (<year>2019</year>) <volume>46</volume>:<fpage>2429</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1007/s00259-019-04450-0</pub-id><pub-id pub-id-type="pmid">31410539</pub-id></citation></ref>
<ref id="B16">
<label>16.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Le Roux</surname> <given-names>PY</given-names></name> <name><surname>Robin</surname> <given-names>P</given-names></name> <name><surname>Delluc</surname> <given-names>A</given-names></name> <name><surname>Abgral</surname> <given-names>R</given-names></name> <name><surname>Le Duc-Pennec</surname> <given-names>A</given-names></name> <name><surname>Nowak</surname> <given-names>E</given-names></name> <etal/></person-group>. <article-title>V/Q SPECT interpretation for pulmonary embolism diagnosis: which criteria to use?</article-title> <source>J Nucl Med.</source> (<year>2013</year>) <volume>54</volume>:<fpage>1077</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.2967/jnumed.112.113639</pub-id><pub-id pub-id-type="pmid">23637200</pub-id></citation></ref>
<ref id="B17">
<label>17.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gopalan</surname> <given-names>D</given-names></name> <name><surname>Delcroix</surname> <given-names>M</given-names></name> <name><surname>Held</surname> <given-names>M</given-names></name></person-group>. <article-title>Diagnosis of chronic thromboembolic pulmonary hypertension</article-title>. <source>Eur Respir Rev</source>. (<year>2017</year>) <volume>26</volume>:<fpage>160108</fpage>. <pub-id pub-id-type="doi">10.1183/16000617.0108-2016</pub-id><pub-id pub-id-type="pmid">28298387</pub-id></citation></ref>
<ref id="B18">
<label>18.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simonneau</surname> <given-names>G</given-names></name> <name><surname>Montani</surname> <given-names>D</given-names></name> <name><surname>Celermajer</surname> <given-names>DS</given-names></name> <name><surname>Denton</surname> <given-names>CP</given-names></name> <name><surname>Gatzoulis</surname> <given-names>MA</given-names></name> <name><surname>Krowka</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Haemodynamic definitions and updated clinical classification of pulmonary hypertension</article-title>. <source>Eur Respir J</source>. (<year>2019</year>) <volume>53</volume>:<fpage>1801913</fpage>. <pub-id pub-id-type="doi">10.1183/13993003.01913-2018</pub-id><pub-id pub-id-type="pmid">30545968</pub-id></citation></ref>
<ref id="B19">
<label>19.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Le Roux</surname> <given-names>PY</given-names></name> <name><surname>Blanc-Beguin</surname> <given-names>F</given-names></name> <name><surname>Bonnefoy</surname> <given-names>PB</given-names></name> <name><surname>Bourhis</surname> <given-names>D</given-names></name> <name><surname>Camilleri</surname> <given-names>S</given-names></name> <name><surname>Moreau-Triby</surname> <given-names>C</given-names></name> <etal/></person-group>. <article-title>SFMN guideline for lung scintigraphy protocols</article-title>. <source>M&#x000E9;d Nucl.</source> (<year>2021</year>) <volume>45</volume>:<fpage>85</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.mednuc.2021.01.001</pub-id></citation>
</ref>
<ref id="B20">
<label>20.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Investigators</surname> <given-names>P</given-names></name></person-group>. <article-title>Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED)</article-title>. <source>JAMA.</source> (<year>1990</year>) <volume>263</volume>:<fpage>2753</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1001/jama.263.20.2753</pub-id><pub-id pub-id-type="pmid">2332918</pub-id></citation></ref>
<ref id="B21">
<label>21.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname> <given-names>N</given-names></name> <name><surname>Fettich</surname> <given-names>J</given-names></name> <name><surname>Kucuk</surname> <given-names>NO</given-names></name> <name><surname>Kraft</surname> <given-names>O</given-names></name> <name><surname>Mut</surname> <given-names>F</given-names></name> <name><surname>Choudhury</surname> <given-names>P</given-names></name> <etal/></person-group>. <article-title>Modified PISAPED criteria in combination with ventilation scintigraphic finding for predicting acute pulmonary embolism</article-title>. <source>World J Nucl Med.</source> (<year>2015</year>) <volume>14</volume>:<fpage>178</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.4103/1450-1147.163248</pub-id><pub-id pub-id-type="pmid">26420988</pub-id></citation></ref>
<ref id="B22">
<label>22.</label>
<citation citation-type="book"><person-group person-group-type="author"><name><surname>Le Roux</surname> <given-names>PY</given-names></name> <name><surname>Bonnefoy</surname> <given-names>PB</given-names></name> <name><surname>Bahloul</surname> <given-names>A</given-names></name> <name><surname>Denizot</surname> <given-names>B</given-names></name> <name><surname>Barres</surname> <given-names>B</given-names></name> <name><surname>Moreau-Triby</surname> <given-names>C</given-names></name> <etal/></person-group>. <article-title>Lung scintigraphy for pulmonary embolism diagnosis in COVID-19 patients: a multicenter study</article-title>. <source>J Nucl Med.</source> (<year>2021</year>). <pub-id pub-id-type="doi">10.2967/jnumed.121.262955</pub-id> [Epub ahead of print].<pub-id pub-id-type="pmid">34649944</pub-id></citation></ref>
<ref id="B23">
<label>23.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Le Roux</surname> <given-names>PY</given-names></name> <name><surname>Robin</surname> <given-names>P</given-names></name> <name><surname>Tromeur</surname> <given-names>C</given-names></name> <name><surname>Davis</surname> <given-names>A</given-names></name> <name><surname>Robert-Ebadi</surname> <given-names>H</given-names></name> <name><surname>Carrier</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Ventilation/perfusion SPECT for the diagnosis of pulmonary embolism: A systematic review</article-title>. <source>J Thromb Haemost.</source> (<year>2020</year>) <volume>18</volume>:<fpage>2910</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1111/jth.15038</pub-id><pub-id pub-id-type="pmid">33433051</pub-id></citation></ref>
<ref id="B24">
<label>24.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Le Roux</surname> <given-names>PY</given-names></name> <name><surname>Pelletier-Galarneau</surname> <given-names>M</given-names></name> <name><surname>De Laroche</surname> <given-names>R</given-names></name> <name><surname>Hofman</surname> <given-names>MS</given-names></name> <name><surname>Zuckier</surname> <given-names>LS</given-names></name> <name><surname>Roach</surname> <given-names>P</given-names></name> <etal/></person-group>. <article-title>Pulmonary scintigraphy for the diagnosis of acute pulmonary embolism: a survey of current practices in Australia, Canada, and France</article-title>. <source>J Nucl Med.</source> (<year>2015</year>) <volume>56</volume>:<fpage>1212</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.2967/jnumed.115.157743</pub-id><pub-id pub-id-type="pmid">26135110</pub-id></citation></ref>
<ref id="B25">
<label>25.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Le Roux</surname> <given-names>PY</given-names></name> <name><surname>Abgral</surname> <given-names>R</given-names></name> <name><surname>Jaffrelot</surname> <given-names>M</given-names></name> <name><surname>Delluc</surname> <given-names>A</given-names></name> <name><surname>Gut-Gobert</surname> <given-names>C</given-names></name> <name><surname>Querellou</surname> <given-names>S</given-names></name> <etal/></person-group>. <article-title>Diagnosis of pulmonary embolism: planar images generated from V/Q SPECT are not a reliable substitute for traditional planar V/Q scan</article-title>. <source>Nucl Med Commun.</source> (<year>2012</year>) <volume>33</volume>:<fpage>695</fpage>&#x02013;<lpage>700</lpage>. <pub-id pub-id-type="doi">10.1097/MNM.0b013e328352c7d2</pub-id><pub-id pub-id-type="pmid">22441133</pub-id></citation></ref>
<ref id="B26">
<label>26.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>J</given-names></name> <name><surname>Larcos</surname> <given-names>G</given-names></name></person-group>. <article-title>Radionuclide lung scans for suspected acute pulmonary embolism: Single photon emission computed tomography (SPECT) or hybrid SPECT/CT?</article-title> <source>J Med Imaging Radiat Oncol.</source> (<year>2019</year>) <volume>63</volume>:<fpage>731</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/1754-9485.12951</pub-id><pub-id pub-id-type="pmid">31515905</pub-id></citation></ref>
<ref id="B27">
<label>27.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Azarian</surname> <given-names>R</given-names></name> <name><surname>Wartski</surname> <given-names>M</given-names></name> <name><surname>Collignon</surname> <given-names>MA</given-names></name> <name><surname>Parent</surname> <given-names>F</given-names></name> <name><surname>Herve</surname> <given-names>P</given-names></name> <name><surname>Sors</surname> <given-names>H</given-names></name> <etal/></person-group>. <article-title>Lung perfusion scans and hemodynamics in acute and chronic pulmonary embolism</article-title>. <source>J Nucl Med.</source> (<year>1997</year>) <volume>38</volume>:<fpage>980</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">9189155</pub-id></citation></ref>
<ref id="B28">
<label>28.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Le Gal</surname> <given-names>G</given-names></name> <name><surname>Le Roux</surname> <given-names>PY</given-names></name></person-group>. <article-title>How to assess quality of primary research studies in the medical literature?</article-title> <source>Semin Nucl Med.</source> (<year>2019</year>) <volume>49</volume>:<fpage>115</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1053/j.semnuclmed.2018.11.007</pub-id><pub-id pub-id-type="pmid">30819391</pub-id></citation></ref>
</ref-list>
</back>
</article>